The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Prescient Therapeutics (PTX) expands its clinical study of patients with relapsed and refractory acute myeloid leukaemia (AML)
  • The addition to the company’s Phase 1b clinical study of PTX-200 and cytarabine follows another complete patient remission, bringing the total in this study to four
  • Three additional patients will now be part of the study at the same dose level of 45 milligrams of the treatment
  • Prescient Therapeutics climbs 28 per cent, trading at 16 cents

Prescient Therapeutics (PTX) is set to expand its clinical study of patients with relapsed and refractory acute myeloid leukemia.

Re-announced today as price sensitive, the company’s Phase 1b clinical study of PTX-200 and cytarabine will expand the cohort at 45 milligrams of PTX-200, following another complete remission and no dose limiting toxicities at this dose level.

Three patients have been treated at 45 milligrams PTX-200 together with cytarabine, with no dose limiting toxicities reported.

One patient in the cohort achieved a CRi, meaning complete remission of disease, with neutrophils and platelets yet to recover to normal levels. This latest patient brings the total of complete remissions in this study to four, while one patient in the prior cohort was determined to have a partial response.

 “It is very satisfying to see another patient with remission in a disease that is so aggressive and fatal,” Prescient CEO and Managing Director Steven Yatomi-Clarke said.

“Despite recent advancements, AML remains a disease of unmet medical need, and we look forward to advancing this study with the aim of benefiting more AML patients.”

This latest data, together with data from the previous Phase 1 monotherapy study, guided the research team to expand enrolment at this dose level to another three patients, to further explore safety and efficacy at this dose level.

Prescient Therapeutics climbed 28 per cent, trading at 16 cents at market close.

PTX by the numbers
More From The Market Online

Week 13 Wrap: Easter bunny delivers new all time high for ASX200

Another week, another all time high. The ASX200 clocked 7,901pts on Thursday for the first time…
The Market Online Video

Market Close: Green lights up on ASX for Easter hunt go

The ASX200 closed the day in record territory - nearly a per cent up with every…

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Market Update: ASX glows red hot with another hit record

The ASX200 is trading up, hitting a new high of 7901 point and eclipsing the last…